Publicacións nas que colabora con M.ª Jesús Lamas Díaz (26)

2021

  1. Predictive value of ERCC2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy

    Cancer Chemotherapy and Pharmacology, Vol. 88, Núm. 5, pp. 813-823

  2. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease: Limits and improvements

    British Journal of Clinical Pharmacology, Vol. 87, Núm. 5, pp. 2216-2227

  3. Therapeutic drug monitoring of voriconazole: Validation of a high performance liquid chromatography method and comparison with an ARK immunoassay

    European Journal of Hospital Pharmacy, Vol. 28, Núm. 3, pp. 154-159

2020

  1. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 8, pp. 1661-1666

  2. Anti-VEGF treatment and response in age-related macular degeneration: Disease’s susceptibility, pharmacogenetics and pharmacokinetics

    Current Medicinal Chemistry, Vol. 27, Núm. 4, pp. 549-569

  3. Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?

    Journal of Chemotherapy, pp. 1-13

  4. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study

    Pharmacotherapy, Vol. 40, Núm. 1, pp. 17-25

2019

  1. An Observational Study of the Efficacy and Safety of Voriconazole in a Real-Life Clinical Setting

    Journal of Chemotherapy, Vol. 31, Núm. 1, pp. 49-57

  2. Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment

    Head and Neck, Vol. 41, Núm. 8, pp. 2704-2715

2018

  1. Longitudinal PET/CT evaluation of TNBS-induced inflammatory bowel disease rat model

    International Journal of Pharmaceutics, Vol. 549, Núm. 1-2, pp. 335-342

  2. Ophthalmic Econazole Hydrogels for the Treatment of Fungal Keratitis

    Journal of Pharmaceutical Sciences, Vol. 107, Núm. 5, pp. 1342-1351

  3. Preclinical characterization and clinical evaluation of tacrolimus eye drops

    European Journal of Pharmaceutical Sciences, Vol. 120, pp. 152-161

2017

  1. In vivo eye surface residence determination by high-resolution scintigraphy of a novel ion-sensitive hydrogel based on gellan gum and kappa-carrageenan

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 114, pp. 317-323

  2. Positron emission tomography for the development and characterization of corneal permanence of ophthalmic pharmaceutical formulations

    Investigative Ophthalmology and Visual Science, Vol. 58, Núm. 2, pp. 772-780

  3. Preclinical PET study of intravitreal injections

    Investigative Ophthalmology and Visual Science, Vol. 58, Núm. 7, pp. 2843-2851

2015

  1. In vitro and in vivo ocular safety and eye surface permanence determination by direct and Magnetic Resonance Imaging of ion-sensitive hydrogels based on gellan gum and kappa-carrageenan

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 94, pp. 342-351

  2. Long Survival and Severe Toxicity under 5-Fluorouracil-Based Therapy in a Patient with Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS

    Mayo Clinic Proceedings, Vol. 90, Núm. 9, pp. 1298-1303

2014

  1. A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer

    Human Genetics, Vol. 133, Núm. 5, pp. 525-534

2013

  1. A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12

    BMC Genomics, Vol. 14, Núm. 1

  2. BMP2/BMP4 colorectal cancer susceptibility loci in northern and southern european populations

    Carcinogenesis, Vol. 34, Núm. 2, pp. 314-318